The company received marketing authorisation approval in the EU earlier this year
On Monday, Biocon Ltd. announced its subsidiary Biocon Biologics Limited received marketing authorisation approval from the United Kingdom’s Medicines and Healthcare products Regulatory Agency for its product YESAFILI®. According to a press release from Biocon, YESAFILI is a biosimilar with comparable efficacy, safety and quality to the reference product Eylea® (aflibercept).1
Earlier this year, YESAFILI underwent the approval process in the European Union. The biosimilar received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use in July and received a marketing authorisation from the European Commission in September.
Biocon’s YESAFILI is intended for treatment of a number of ocular conditions, including neovascular age-related macular degeneration, visual impairment due to myopic choroidal neovascularisation, visual impairment due to diabetic macular oedema and visual impairment due to macular oedema secondary to retinal vein occlusion. In the news release, Biocon expressed that the biosimilar approval will help the company expand its product portfolios in ophthalmology, diabetes care and oncology.
In July, Shreehas Tambe, CEO and managing director of Biocon Biologics, commented on the positive CHMP opinion for YESAFILI.2 "This is further confirmation of our strong commitment to providing high-quality and affordable medicines and represents another significant milestone as we continue to expand our biosimilar offerings across the globe,” Tambe said.